Allarity Therapeutics, Inc. (NASDAQ:ALLR)
| Market Cap | 15.75M-43.8% |
| Revenue (ttm) | 345.00K |
| Net Income | -12.33M+48.8% |
| EPS | -0.78+91.5% |
| Shares Out | 15.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,716 |
| Open | 1.03 |
| Previous Close | 0.98 |
| Day's Range | 0.99 - 1.04 |
| 52-Week Range | 0.77 - 1.84 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ALLR
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
$ALLR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALLR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALLR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALLR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ALLR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALLR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALLR
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $242.23K |
Estimated from each fund’s disclosed top holdings × AUM
ALLR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ALLR’s recent data — informational, not investment advice